Genetic Predisposition to Parkinson's Disease and Cancer

被引：5

作者：

Li, Zhiming ^{[1
]}

Lin, Qing ^{[1
,2
]}

Ma, Qilin ^{[2
]}

Lu, Congxia ^{[2
]}

Tzeng, Chi-Meng ^{[1
]}

机构：

[1] Xiamen Univ, Sch Pharmaceut Sci, Xiamen 361005, Fujian, Peoples R China

[2] Xiamen Univ, Affiliated Hosp 1, Dept Neurol, Xiamen 361003, Fujian, Peoples R China

来源：

CURRENT CANCER DRUG TARGETS | 2014年 / 14卷 / 03期

基金：

中国国家自然科学基金;

关键词：

Cancer; genes; parkinson's disease; pathways; CYCLIN-DEPENDENT KINASE-5; ALPHA-SYNUCLEIN; DOWN-REGULATION; MITOCHONDRIAL PATHOLOGY; INDUCED APOPTOSIS; OXIDATIVE STRESS; DNA-DAMAGE; LRRK2; PROTEIN; DJ-1;

D O I：

10.2174/1568009614666140312145936

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Parkinson's disease (PD) and cancer are often thought of as two sides of the same coin. At first glance, cancer and PD appear to have little in common. PD is caused by the degeneration of dopaminergic neurons, whereas cancer results from the uninhibited growth of tumor cells. Increasing numbers of genetic studies suggest that the pathogenesis of PD and cancer may involve similar genes, pathways, and mechanisms. The differences in the pathological and cellular mechanisms, and the associated genetic mutations, may result in two such divergent diseases. In this article, we highlight some molecular mechanisms and key biomarkers which might cause those two diseases from misfolding and degradation of proteins, mitochondrial damage, oxidative stress response, cell cycle control and DNA repair, and the PI3K/AKT/mTOR pathway, in order to provide help to the understanding and treatment of these two diseases.

引用

页码：310 / 321

页数：12

共 131 条

[21] mTOR signaling in disease [J].

Dazert, Eva ;

Hall, Michael N. .

CURRENT OPINION IN CELL BIOLOGY, 2011, 23 (06) :744-755

[22] Clinical features and neuroimaging of PARK7-linked parkinsonism [J].

Dekker, M ;

Bonifati, V ;

van Swieten, J ;

Leenders, N ;

Galjaard, RJ ;

Snijders, P ;

Horstink, M ;

Heutink, P ;

Oostra, B ;

van Duijn, C .

MOVEMENT DISORDERS, 2003, 18 (07) :751-757

[23] PET neuroimaging and mutations in the DJ-1 gene [J].

Dekker, MCJ ;

Eshuis, SA ;

Maguire, RP ;

Veenma-van der Duijn, L ;

Pruim, J ;

Snijders, PJLM ;

Oostra, BA ;

van Duijn, CM ;

Leenders, KL .

JOURNAL OF NEURAL TRANSMISSION, 2004, 111 (12) :1575-1581

[24] Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y [J].

Deng, H ;

Jankovic, J ;

Guo, Y ;

Xie, WJ ;

Le, WD .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 337 (04) :1133-1138

[25] Alterations in the common fragile site gene Parkin in ovarian and other cancers [J].

Denison, SR ;

Wang, F ;

Becker, NA ;

Schüle, B ;

Kock, N ;

Phillips, LA ;

Klein, C ;

Smith, DI .

ONCOGENE, 2003, 22 (51) :8370-8378

[26] Parkinson's disease and cancer: two wars, one front [J].

Devine, Michael J. ;

Plun-Favreau, Helene ;

Wood, Nicholas W. .

NATURE REVIEWS CANCER, 2011, 11 (11) :812-+

[27] A decade of CDK5 [J].

Dhavan, R ;

Tsai, LH .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (10) :749-759

[28] PROBLEM SITUATIONS IN THE TREATMENT OF PARALYSIS AGITANS [J].

DOSHAY, LJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1954, 156 (07) :680-684

[29] Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin [J].

Exner, Nicole ;

Treske, Bettina ;

Paquet, Dominik ;

Holmström, Kira ;

Schiesling, Carola ;

Gispert, Suzana ;

Carballo-Carbajal, Iria ;

Berg, Daniela ;

Hoepken, Hans-Hermann ;

Gasser, Thomas ;

Kr ger, Rejko ;

Winklhofer, Konstanze F. ;

Vogel, Frank ;

Reichert, Andreas S. ;

Auburger, Georg ;

Kahle, Philipp J. ;

Schmid, Bettina ;

Haass, Christian .

JOURNAL OF NEUROSCIENCE, 2007, 27 (45) :12413-12418

[30] Genetics of Parkinson disease: paradigm shifts and future prospects [J].

Farrer, MJ .

NATURE REVIEWS GENETICS, 2006, 7 (04) :306-318

← 1 2 3 4 5 6 7 8 9 10 →